Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according […]
The post ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com